Uppsala 20th November 2018


New positive study results with PharmaShell®


A recently completed animal study in which PharmaShell® coated drug particles have been administered in various ways has yielded positive results showing that the use of PharmaShell® is very flexible. We have obtained results that show that we can administer a high dose of drug in small injection volume while maintaining long drug release. This is a great advantage in the development of long depot preparations.


We have also shown the possibility of dividing a dose at several injection sites and still obtaining the same control over the release of drugs into the blood. Furthermore, in this study, we demonstrated that we can administer PharmaShell® intramuscularly, which, as expected, produced a slightly faster release than subcutaneous administration.


Nanexa’s CEO David Westberg comments:


These results were expected and help us build the preclinical results bank that shows how PharmaShell® works in different situations. This is important, not least in contact with the big pharmaceutical companies.


For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail:


About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.